Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC0062 in IgA Nephropathy (SUCCESS-1)
NCT06819826Phase 3Recruiting
- Sponsor
- BioCity Biopharma
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing SC0062 group with Placebo group (2 arms). Primary endpoint: Change from baseline in 24-hour urine protein-to-creatinine ratio at 36 weeks. Started Feb 2025; status: recruiting.
02
Drugs
SC0062
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06819826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06819826.